Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Prediction of Peritoneal Dissemination of Digestive Tumors Through the Study of Circulating Tumor DNA (PREDIPER)

5 maggio 2026 aggiornato da: Assistance Publique - Hôpitaux de Paris

Prédiction de la dissémination péritonéale Des Tumeurs Digestives Par étude de l'ADN Tumoral Circulant

The peritoneum is a relatively frequent metastatic site in digestive tumors (colon, stomach, pancreas) and is characterized by a poorer prognosis compared with other metastatic sites such as the lung or liver. Its dissemination pathway is complex and most often involves crossing the hemato-peritoneal barrier. This type of metastasis is difficult to visualize on imaging at an early stage, and surgical exploration may be required. In gastric cancer in particular, exploratory laparoscopy is part of the initial staging work-up for locally advanced tumors to assess the presence or absence of peritoneal metastases. It is therefore important to develop new, less invasive detection or prediction methods.

Circulating tumor DNA (ctDNA) is a promising non-invasive blood biomarker that can assist clinicians as a prognostic/predictive biomarker and/or a tool for monitoring response to anti-tumor therapies. This marker is most often assessed in plasma, but recent data suggest that tumor DNA may also be detected in other biological fluids such as peritoneal fluid. A preliminary study conducted by our team showed the ability to detect tumor DNA in peritoneal fluid from patients with peritoneal carcinomatosis of various origins, with a sensitivity of 75%. In gastric cancer, a recent meta-analysis demonstrated an increased risk of peritoneal metastases when peritoneal tumor DNA was positive (RR 13.81 [95% CI, 8.11-23.53]), as well as a reduction in 3-year recurrence-free survival (RR 5.37 [95% CI, 1.39-20.74]) and overall survival (HR 4.13 [95% CI, 1.51-11.32]).

The objective of this cohort is to evaluate the prognostic impact of circulating tumor DNA (ctDNA) in plasma and/or peritoneal fluid on the risk of developing peritoneal metastases. The primary endpoint is: Peritoneal recurrence rate according to tumor DNA positivity status (positive vs negative).

Panoramica dello studio

Stato

Non ancora reclutamento

Descrizione dettagliata

After screening, verification of inclusion and exclusion criteria, information and consent, patients will be enrolled in the study.

Several samples will be collected at different time points during patient management, in addition to samples already performed as part of routine care. No intervention or sampling will occur at a time point specifically required for research purposes. Blood and peritoneal fluid samples will always be collected concomitantly. They will then be transported to the molecular biology laboratory for initial DNA extraction. After extraction, samples will be stored at -80 °C until analysis.

The treatments offered to the patient follow standard-of-care recommendations and are not modified by participation in the study.

Three independent cohorts will be evaluated: gastric cancer, colon cancer, and pancreatic cancer.Depending on the type of cancer and the therapeutic strategy, different samples will be collected.

Systematic sampling:

Plasma: at diagnosis, at the time of surgery, in the early postoperative period, and 1 month after surgery (during the postoperative visit).

Peritoneal fluid: at the time of surgery and in the early postoperative period.

Specific sampling:

Peritoneal fluid: during pre-therapeutic exploratory laparoscopy (gastric cancer) or during diverting colostomy (obstructive colon cancer).

In total:

Gastric cancer: 3 peritoneal fluid samples and 4 blood samples.

Colon cancer: 2 peritoneal fluid samples and 3 blood samples systematically, plus 1 optional blood and peritoneal fluid sample (only in case of diverting colostomy).

Pancreatic cancer: 2 peritoneal fluid samples and 3 systematic blood samples, plus 1 optional blood sample (in case of neoadjuvant treatment).

Blood sampling:

2 EDTA tubes (molecular biology)

Peritoneal fluid sampling:

2 dry tubes (molecular biology, pathology)

For intraoperative sampling, a peritoneal washing is performed with 200 mL of 0.9% NaCl instilled into the abdominal cavity; then 50 mL are collected from the pouch of Douglas.

For the postoperative period, the sample will be collected between postoperative day 2 and day 5 directly from the drainage fluid (collected from the drain reservoir left in place at the end of surgery).

ctDNA analysis: NGS (next-generation sequencing), or high-throughput sequencing, is a molecular biology method that enables the rapid sequencing of millions of DNA molecules simultaneously and is used to identify point mutations as well as insertions, duplications, and deletions. It will be used for both plasma analysis and peritoneal fluid analysis.

Tipo di studio

Osservativo

Iscrizione (Stimato)

300

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

All patients treated for a histologically proven, localized adenocarcinoma of gastric or pancreatic or colorectal, will be enrolled in this prospective cohort study after receiving and signed a specific consent information form.

Descrizione

Inclusion Criteria:

  • Age > 18 years
  • Signed non-opposition form
  • For gastric cancer: histologically confirmed gastric adenocarcinoma >T2 and/or N+; for colon cancer: histologically confirmed colonic adenocarcinoma >T2; for pancreatic cancer: histologically confirmed pancreatic adenocarcinoma >T2
  • No metastases on the initial staging work-up
  • No contraindication to curative-intent surgical treatment

Exclusion Criteria:

  • Primary tumor metastatic at diagnosis
  • Presence of ascites or distant metastases
  • Synchronous cancer or prior history of cancer within the past 5 years
  • Contraindication to curative surgical treatment
  • Any patient unable to comply with the study's medical follow-up for geographic, social, or psychological reasons
  • Patients under legal guardianship/protection, or unable to read, understand, and sign the information notice and consent form
  • Patients not affiliated with the social security system

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
localized gastric cancer
resectable tumor receiving neoajuvant chemotherapy and curative gastrectomy
localized colorectal cancer
resectable tumor receiving neoajuvant chemotherapy or not and curative colectomy
localized pancreatic cancer
resectable tumor receiving neoajuvant chemotherapy or not and curative pancreatectomy

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
peritoneal progression free survival (PPFS)
Lasso di tempo: Time from the start of treatment until peritoneal recurrence assessed up to 36 months
PPFS will be evaluated according to the circulating tumor DNA in the blood and in the peritoneal fluid
Time from the start of treatment until peritoneal recurrence assessed up to 36 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
disease free survival (DFS)
Lasso di tempo: Time from the start of treatment until recurrence assessed up to 36 months
DFS will be evaluated according to the circulating tumor DNA in the blood and in the peritoneal fluid
Time from the start of treatment until recurrence assessed up to 36 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 giugno 2026

Completamento primario (Stimato)

1 giugno 2033

Completamento dello studio (Stimato)

1 giugno 2033

Date di iscrizione allo studio

Primo inviato

10 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

5 maggio 2026

Primo Inserito (Effettivo)

8 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi